Oncology

The Pharmacy Times® Oncology resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.

What can we help you find?
[[thumbnail_alt_text]]
Review of the pharmacist’s role in outpatient care for acute myeloid leukemia.
[[thumbnail_alt_text]]
The cause of the majority of rare diseases is associated with 80% of the cases being genetically linked due to inheritance of mutated genes.
[[thumbnail_alt_text]]
Over time, hub operations have matured to act as sort of a middleman between manufacturers and specialty pharmacies.
[[thumbnail_alt_text]]
Description of the traditional inpatient administrations versus outpatient treatment processes in acute myeloid leukemia.
[[thumbnail_alt_text]]
According to study findings published in Cancer, mammography screenings reduce the rates of advanced and fatal cancers by more than 40%.
[[thumbnail_alt_text]]
Many pharmaceutical manufacturers consider accreditation a prerequisite when either building their network or adding pharmacies to their network.
[[thumbnail_alt_text]]
New treatments with biological agents and vaccines are creating a pathway for patients with metastatic CRC.
[[thumbnail_alt_text]]
The approval is based on an interim analysis from the phase 3 IMpower110 study, which showed atezolizumab monotherapy improved overall survival by 7.1 months compared with chemotherapy in people with high PD-L1 expression, according to a press release.
[[thumbnail_alt_text]]
The anti-cancer medicine venetoclax may improve the current therapy for estrogen receptor-positive (ER+) breast cancer.
[[thumbnail_alt_text]]
Ripretinib is indicated for adult patients who have received prior treatment with 3 or more kinase inhibitor therapies, including imatinib, according to an FDA press release.
[[thumbnail_alt_text]]
Experts discuss the identification and Medical Utilization Evaluation of patients with newly diagnosed acute myeloid leukemia.
[[thumbnail_alt_text]]
Although the average wholesale price of the agents is more than $13,000, the investigators found that 9% of patients had a 0% co-pay throughout the 6-month period.